ArticleJournal of extracellular vesicles2026
Surface N-Glycosylation Dictates MSC-EV Uptake and CCR2-Driven Monocyte Recruitment to Inflamed Endothelium Under Shear Flow.
Article in Journal of extracellular vesicles, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Size-Based Proteomic Signatures of Extracellular Vesicles Derived from Umbilical Cord Mesenchymal Stem Cells Fractionated by EXODUS.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Mesenchymal stromal cell-derived extracellular vesicles (MSC-EV) hold promising potential for immunomodulation and tissue regeneration, especially for treating ischemia-reperfusion injury (IRI). However, their therapeutic use is hindered by challenges in tissue targeting and incomplete understanding of their functional mechanisms. Upon systemic administration, MSC-EV first encounter IRI-activated endothelium, whose response would determine the nature and extent of subsequent immune cell infiltration and inflammation, with monocytes shaping the type of immune response. Our previous work showed that surface N-glycans are key for MSC-EV interaction with endothelial cells. Here, we investigate the role of N-glycosylation in MSC-EV interaction with TNF-activated endothelial cells and subsequent monocyte rolling and adhesion. Using static and dynamic flow in vitro models, we show that depletion of surface N-glycans specifically targeted MSC-EV to inflamed endothelium. Conversely, while intact MSC-EV inhibited monocyte adhesion and fostered MSC recruitment to endothelial cells, this was lost upon N-glycan depletion. Finally, our results suggest that MSC-EV-mediated modulation of the MCP-1/CCR2 interaction may underlie the reduced monocyte infiltration into inflamed endothelium. These findings highlight the role of N-glycosylation in the immunomodulatory activity of MSC-EV, offering a potential mechanism of action and suggesting that glycoengineered MSC-EV may enhance their therapeutic effectiveness in inflammatory and ischemic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.